New $250M Iceland Factory Puts Alvogen in Biosimilar Race

Dec 10, 2013


Iceland is joining the race to make generic versions of complex biotech drugs with an investment of $250 million in development and manufacturing by Alvotech, a sister company of privately owned U.S.-based Alvogen.

The money will pay for a 11,800 square meter facility in Iceland that will open in early 2016. The company hopes to have its own biosimilars in the market by 2018 when patents for a number of high-priced biologic drugs will be rolling off.

Read the Rueters press release

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments